Insider Selling: Zynex, Inc. (NASDAQ:ZYXI) CFO Sells 10,000 Shares of Stock

Zynex, Inc. (NASDAQ:ZYXI - Get Free Report) CFO Daniel J. Moorhead sold 10,000 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.15, for a total value of $71,500.00. Following the completion of the sale, the chief financial officer now directly owns 10,050 shares of the company's stock, valued at approximately $71,857.50. This trade represents a 49.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Zynex Stock Up 1.1 %

Shares of Zynex stock traded up $0.08 during midday trading on Friday, hitting $7.35. The company's stock had a trading volume of 49,406 shares, compared to its average volume of 70,648. The firm has a market capitalization of $234.07 million, a P/E ratio of 49.00 and a beta of 0.81. The stock has a 50-day simple moving average of $7.75 and a 200-day simple moving average of $8.03. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. Zynex, Inc. has a 1-year low of $7.00 and a 1-year high of $13.19.

Institutional Trading of Zynex

Institutional investors have recently bought and sold shares of the company. Janney Montgomery Scott LLC boosted its position in Zynex by 10.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 159,259 shares of the company's stock valued at $1,276,000 after purchasing an additional 14,820 shares during the last quarter. Barclays PLC boosted its position in Zynex by 43.3% during the third quarter. Barclays PLC now owns 28,821 shares of the company's stock valued at $236,000 after purchasing an additional 8,713 shares during the last quarter. Jane Street Group LLC boosted its position in Zynex by 8.9% during the third quarter. Jane Street Group LLC now owns 23,530 shares of the company's stock valued at $192,000 after purchasing an additional 1,929 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Zynex by 3.3% during the third quarter. JPMorgan Chase & Co. now owns 40,985 shares of the company's stock valued at $334,000 after purchasing an additional 1,318 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in Zynex during the fourth quarter valued at $26,000. Institutional investors and hedge funds own 29.68% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $17.00 target price on shares of Zynex in a research report on Friday, December 6th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.